Skip to main content
OpenTrials

Clinical trial condition

Poxviridae Infections

Explore clinical trials studying Poxviridae Infections. Study availability and eligibility vary by location and protocol.

166 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Poxviridae Infections trial results

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • Univ. of Rochester AVEG Rochester, New York, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details
Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +15 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details
Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

NCT00000767

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • Univ. of Rochester AVEG Rochester, New York, United States
  • JHU AVEG Pittsburgh, Pennsylvania, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
View Trial Details
Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NCT00000866

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • JHU AVEG Baltimore, Maryland, United States
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details

Related conditions